ACRO Forecasts Radiologist Surplus

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

OAK BROOK, Ill--Young physicians seeking careers in radiation on-cology may have severely limited employment opportunities in the foreseeable future, according to the American College of Radiation Oncology (ACRO). The College forecasts that up to 1,000 radiation oncologists will be either underemployed or unemployed shortly after the year 2000.

OAK BROOK, Ill--Young physicians seeking careers in radiationon-cology may have severely limited employment opportunities inthe foreseeable future, according to the American College of RadiationOncology (ACRO). The College forecasts that up to 1,000 radiationoncologists will be either underemployed or unemployed shortlyafter the year 2000.

The College's Personnel Needs Assessment Committee found thatapproximately 800 new radiation oncologists will enter the jobmarket in the next 5 years while fewer than 200 existing radiationoncologists will leave the workforce during the same period.

Quality of Training Affected

The Committee anticipates that the annual average caseload isexpected to remain between 210 and 216 patients through the year2004. A surplus of radiation oncologists may decrease patientcaseload at large medical centers and limit the number of patientsavailable for resident training, thereby adversely affecting thequality of training available to radiation oncology residents.

"The word needs to get out," said ACRO president WilliamD. Bloomer. "Unlike medical subspecialists who can fall backon general internal medicine if their specialty practice falters,radiation oncologists have no fall-back position without majorre-training."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content